SpotCheck: Comparison of Enhanced Telemedicine Versus In-Person Evalution for the Diagnosis of Skin Cancer.
Brief description of study
The aim of this pilot is to test a novel, telemedicine-based skin lesion diagnostic platform (SpotCheck) that has the potential to improve access to needed dermatologic care to those living in medically underserved areas.
In this study we will recruit participants with 1-3 skin lesions concerning for skin cancer. Each concerning lesion will be evaluated by an enhanced telemedicine method using a clinical image, a dermoscopic image, and a measurement by Nevisense, a low-cost skin cancer diagnostic device currently FDA-cleared for use in dermatologist’s offices.
To learn more about this study, call 212-263-5244, or fill out the form below.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
